Current possibilities of combined hormonal contraception
The paper presents information about global trends in the use of combined hormonal contraception. It describes the evolutionary aspects of combined oral contraceptive pills and different modes of their use. The paper provides rationales for and benefits of a 91-day fixed extended contraceptive regimen using containing ethinyl estradiol and levonorgestrel. It also describes information on the efficacy, safety, and acceptability of the ethinyl estradiol and levonorgestrel combination with a 7-day continuation of low-dose ethinyl estradiol use. The authors discuss the issues of counseling of women opting for or already using a fixed extended hormonal contraception regimen.Aganezova N.V., Aganezov S.S.
Keywords
hormonal contraception
combined oral contraceptives
levonorgestrel
ethinyl estradiol
fixed extended regimen
modell libera
gestagens
References
1. Hooper D.J. Attitudes, awareness, compliance and preferences among hormonal contraception users: a global, cross-sectional, self-administered, online survey. Clin. Drug Investig. 2010; 30(11): 749-63.
2. Skouby S.O. Contraceptive use and behavior in the 21st century: a comprehensive study across five European countries. Eur. J. Contracept. Reprod. Health Care. 2010; 15(Suppl. 2): S42-53.
3. Egarter C., Frey Tirri B., Bitzer J., Kaminskyy V., Oddens B.J., Prilepskaya V. et al. Women’s perceptions and reasons for choosing the pill, patch, or ring in the CHOICE study: a cross-sectional survey of contraceptive method selection after counseling. BMC Women’s Health. 2013; 13: 9.
4. Агеева Л.И., Александрова Г.А., Зайченко Н.М., Кириллова Г.Н., Леонов С.А., Огрызко Е.В., Титова И.А., Харькова Т.Л., Чумарина В.Ж., Шубочкина Е.М. Здравоохранение в России. 2017: Стат.сб./Росстат. М.; 2017. [Ageeva L.I., Alexandrova G.A., Zaichenko N.M., Kirillova G.N., Leonov S.A., Ogryzko E.V., Titova I.A., Kharkova T.L., Chumarina V.Zh., Shubochkina E.M. Health care in Russia. 2017: Stat.sb./ Rosstat. Moscow; 2017 (in Russian)]
5. Combined hormonal contraception and the risk of venous thromboembolism: a guideline. Practice Committee of the American Society for Reproductive Medicine. Electronic address: ASRM@asrm.org1; Practice Committee of the American Society for Reproductive Medicine. Fertil. Steril. 2017;107(1): 43-51.
6. Nappi R.E., Paoletti A.M., Volpe A., Chiovato L., Howard B., Weiss H., Ricciotti N. Multinational, multicentre, randomised, open-label study evaluating the impact of a 91-day extended regimen combined oral contraceptive, compared with two 28-day traditional combined oral contraceptives, on haemostatic parameters in healthy women. Eur. J. Contracept. Reprod. Health Care. 2014; 19(4): 285-94.
7. Krishnan S., Kiley J. The lowest-dose, extended-cycle combined oral contraceptive pill with continuous ethinyl estradiol in the United States: a review of the literature on ethinyl estradiol 20 μg/levonorgestrel 100 μg + ethinyl estradiol 10 μg. Int. J. Women’s Health. 2010; 2: 235-9.
8. Martinez F., Ramirez I., Perez-Campos E., Latorre K., Lete I. Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis. Eur. J. Contracept. Reprod. Health Care 2012; 17: 7-29.
9. Stewart M., Black K. Choosing a combined oral contraceptive pill. Aust. Prescr. 2015; 38(1): 6-11.
10. Nappi R.E., Kaunitz A.M., Bitzer J. Extended regimen combined oral contraception: A review of evolving concepts and acceptance by women and clinicians. Eur. J. Contracept. Reprod. Health Care. 2016; 21(2): 106-15.
11. Roth K., Zahradnik H.P., Schäfer W.R. Effects of different progestins on prostaglandin biosynthesis in human endometrial explants. Contraception. 2018; Aug 13. pii: S0010-7824(18)30394-9.
12. Uçar T., Timur Taşhan S., Aksoy Derya Y., Nacar G. An analysis of dysmenorrhoea and depressive symptoms in university students: A case-control study. Int. J. Nurs. Pract. 2018; 24(5): e12678.
13. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., Lanctôt K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry. 2010; 67(5): 446-57.
14. Fan C., Song Q., Wang P., Li Y., Yang M., Liu B., Yu S.Y. Curcumin protects against chronic stress-induced dysregulation of neuroplasticity and depression-like behaviors via suppressing IL-1β pathway in pats. Neuroscience. 2018; Sep 27. pii: S0306-4522(18)30633-X.
15. Brynhildsen J. Combined hormonal contraceptives: prescribing patterns, compliance, and benefits versus risks. Ther. Adv. Drug Saf. 2014;5(5): 201-13.
16. Cibula D., Zikan M., Dusek L., Majek O. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev. Anticancer Ther. 2011; 11(8): 1197-207.
17. Аганезова Н.В., Аганезов С.С. Новые технологии в гинекологии: фиксированный пролонгированный режим гормональной контрацепции. Акушерство и гинекология. 2017; 3: 154-9. [Aganezova N.V., Aganezov S.S. New technologies in gynecology: A fixed extended hormonal contraceptive regimen. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2017; (3): 154-9. (in Russian)] http://dx.doi.org/10.18565/aig.2017.3.154-9
18. Kroll R., Reape K.Z., Margolis M. The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol. Contraception. 2010; 81(1): 41-8.
19. IMS Retail Audit Data Base, 2016.
20. Benson L.S., Micks E.A. Why Stop Now? Extended and continuous regimens of combined hormonal contraceptive methods. Obstet. Gynecol. Clin. North Am. 2015; 42(4): 669-81.
21. Edelman A., Micks E., Gallo M.F., Jensen J.T., Grimes D.A. Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception. Cochrane Database Syst. Rev. 2014; (7): CD004695.
22. Nappi R.E., Lete I., Lee L.K., Flores N.M., Micheletti M.C., Tang B. Real-world experience of women using extended-cyclevs monthly-cycle combined oral contraception in the United States: the National Health and Wellness Survey. BMC Womens Health. 2018;18(1): 22.
23. Kroll R., Seidman L., Ricciotti N., Howard B., Weiss H. A phase 1, multicentre, openlabel study to evaluate ovarian follicular activity and hormone levels with an extended-regimen combined oral contraceptive with lowdose ethinyl estradiol supplementation. Eur. J. Contracept. Reprod. Health Care. 2015;20(4): 249-58.
24. Mendoza N., Lobo P., Lertxundi R., Correa M., Gonzalez E., Salamanca A., Sánchez-Borrego R. Extended regimens of combined hormonal contraception to reduce symptoms related to withdrawal bleeding and the hormone-free interval: a systematic review of randomised and observational studies. Eur. J. Contracept. Reprod. Health Care. 2014; 19(5): 321-39.
25. Frederick C.E., Edelman A., Carlson N.E., Rosenberg K.D., Jensen J.T. Extended-use oral contraceptives and medically induced amenorrhea: attitudes, knowledge and prescribing habits of physicians. Contraception. 2011; 84(4): 384-9.
26. Seval D.L., Buckley T., Kuehl T.J., Sulak P.J. Attitudes and prescribing patterns of extended-cycle oral contraceptives. Contraception. 2011; 84(1): 71-5.
Received 13.09.2018
Accepted 21.09.2018
About the Authors
Aganezova, Natalia V., MD, Associate Professor, Department of Obstetrics and Gynecology, I.I. Mechnikov North-West State Medical University,Ministry of Health of Russia. 191015, Russia, St. Petersburg, Kirochnaya str. 41. Tel.: +79219462273. Е-mail: aganezova@mail.ru
Aganezov, Sergey S., PhD, Associate Professor, Department of Obstetrics and Gynecology, I.I. Mechnikov North-West State Medical University,
Ministry of Health of Russia. 191015, Russia, St. Petersburg, Kirochnaya str. 41. Tel.: +79219385073. Е-mail: aganezov@mail.ru
For citations: Aganezova N.V., Aganezov S.S. Current possibilities of combined hormonal contraception. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2018; (10): 129-35. (in Russian)
https://dx.doi.org/10.18565/aig.2018.10.129-135
Similar Articles
